Mortimer J, Flournoy N, Livingston R B, Stephens R L
Cancer. 1985 Nov 15;56(10):2376-80. doi: 10.1002/1097-0142(19851115)56:10<2376::aid-cncr2820561005>3.0.co;2-s.
Sixty-four patients with disseminated breast cancer were treated with an aggressive chemotherapy program of prednisone, methotrexate, 5-fluorouracil, Adriamycin (doxorubicin) and cyclophosphamide (PM-FAC). A response rate of 76% was seen in 44 estrogen receptor (ER) negative patients, with 26% achieving complete responses. Forty-two percent of 20 ER positive and unknown patients demonstrated a response, but in none was a complete response achieved. Median response duration was 9 months for complete responders and 5 months for partial responders. The median survival for both groups of patients was 13 months. However, survival among the responding patients was inferior for the ER negative group (median, 14 versus 20 months; P = 0.05). These findings suggest selective sensitivity of ER negative breast cancer to Adriamycin-containing chemotherapy. Despite aggressive chemotherapy, no durable remissions were achieved. Relapse occurred at sites of known prior involvement, and in the central nervous system de novo, especially in the ER negative patients.
64例转移性乳腺癌患者接受了泼尼松、甲氨蝶呤、5-氟尿嘧啶、阿霉素（多柔比星）和环磷酰胺（PM-FAC）的强化化疗方案。44例雌激素受体（ER）阴性患者的缓解率为76%，其中26%达到完全缓解。20例ER阳性和ER状态不明的患者中有42%出现缓解，但无一例达到完全缓解。完全缓解者的中位缓解持续时间为9个月，部分缓解者为5个月。两组患者的中位生存期均为13个月。然而，ER阴性组缓解患者的生存期较差（中位生存期分别为14个月和20个月；P=0.05）。这些发现提示ER阴性乳腺癌对含阿霉素化疗具有选择性敏感性。尽管进行了强化化疗，但未实现持久缓解。复发发生在先前已知受累的部位，以及中枢神经系统新发部位，尤其是ER阴性患者。
